DeepCure, a domestic medical device venture, said on the 21st that it announced the first-in-human (FIH) clinical results of its hypertension treatment device "HyperCure."
The announcement was made at EuroPCR 2026, an international cardiovascular conference that opened in Paris, France, on the 19th (local time) and runs through today. It covers the three-month results of HyperCure's clinical trial.
The clinical trial enrolled 10 patients with resistant hypertension whose blood pressure was not controlled despite taking three or more antihypertensive drugs.
According to DeepCure, at three months after the procedure, 24-hour ambulatory systolic blood pressure (24-h ASBP) decreased by a median of 25.0 mmHg, and office systolic blood pressure decreased by 39.5 mmHg. In addition, 70% of patients were said to have reached the target blood pressure of below 140 mmHg.
DeepCure said patients also reduced the number of antihypertensive drugs they were taking. The number of medications taken by trial participants decreased from a baseline median of six to 4.5 at three months.
EuroPCR is an international academic conference in the field of cardiovascular medicine organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI). It is known to draw more than 12,000 interventional specialists from over 120 countries every year.
This announcement involved seven institutions in Korea, including Hanyang University Hospital, Seoul National University Hospital, Seoul National University Bundang Hospital, Severance Hospital, Asan Medical Center, Seoul St. Mary's Hospital, and Chonnam National University Hwasun Hospital.
DeepCure is developing a renal denervation (RDN) medical device. It also brought on Raymond Townsend, an emeritus professor at the Perelman School of Medicine at the University of Pennsylvania and a world authority in hypertension, as an adviser.